logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8877768 B1

PDFFull Text
Date of Patent:
Nov. 04, 2014

Filed:

Sep. 13, 2010

Method and composition for treating alzheimer-type dementia

Applicants:

Thomas N. Chase, Washington, DC (US);

Kathleen E. Clarence-smith, Washington, DC (US);

Inventors:

Thomas N. Chase, Washington, DC (US);

Kathleen E. Clarence-Smith, Washington, DC (US);

Assignee:

Chase Pharmaceuticals Corporation, Washington, DC (US);

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Svetlana M Ivanova

Int. Cl.
CPC ...
A01N 43/42 (2006.01); A01N 43/36 (2006.01); A61K 31/44 (2006.01); A61K 31/55 (2006.01); A61K 31/166 (2006.01); A61K 31/353 (2006.01); A61K 31/496 (2006.01); A61K 31/27 (2006.01); A61K 9/20 (2006.01); A61K 31/4178 (2006.01); A61K 9/00 (2006.01); A61K 31/46 (2006.01); A61K 31/454 (2006.01); A61K 31/439 (2006.01); A61K 9/48 (2006.01); A61K 31/5377 (2006.01); A61K 31/407 (2006.01); A61K 31/445 (2006.01); A61K 31/4184 (2006.01); A61K 45/06 (2006.01); A61K 31/473 (2006.01);
U.S. Cl.
CPC ...
A61K 31/445 (2013.01); A61K 31/55 (2013.01); A61K 31/166 (2013.01); A61K 31/353 (2013.01); A61K 31/496 (2013.01); A61K 31/27 (2013.01); A61K 9/2018 (2013.01); A61K 31/4178 (2013.01); A61K 9/0056 (2013.01); A61K 9/2054 (2013.01); A61K 31/46 (2013.01); A61K 31/454 (2013.01); A61K 31/439 (2013.01); A61K 9/4808 (2013.01); A61K 31/5377 (2013.01); A61K 9/2059 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 45/06 (2013.01); A61K 9/205 (2013.01); A61K 31/473 (2013.01);
Abstract

There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HTreceptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.

Find Patent Forward Citations

Loading…